BioCentury | May 7, 2019
Clinical News

More SMA data at AAN suggest new therapies could displace Spinraza

...who have been previously treated with an SMN-targeted therapy or Roche's now discontinued SMA candidate olesoxime...
BioCentury | Jun 8, 2018
Clinical News

Roche discontinues SMA candidate

...Roche (SIX:ROG; OTCQX:RHHBY) said it will discontinue development of spinal muscular atrophy candidate olesoxime (RG6083, TRO19622...
...2015 (see BioCentury, Jan. 19, 2015) . Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Olesoxime (RG6083, TRO19622...
...Indication: Treat spinal muscular atrophy (SMA) Endpoint: NA Status: Development discontinued Milestone: NA Erin McCallister olesoxime (RG6083, TRO19622) RG7916...
BioCentury | Jun 1, 2018
Company News

Roche discontinues SMA candidate

...Roche (SIX:ROG; OTCQX:RHHBY) said it will discontinue development of spinal muscular atrophy candidate olesoxime (RG6083, TRO19622...
...a worsening in motor function. The pharma also cited in its reasoning difficulties in formulating olesoxime...
...type 1. It is an oral survival of motor neuron 2 centromeric (SMN2) splicing modifier. Olesoxime...
BioCentury | Jun 28, 2017
Company News

Scholar Rock developing lead candidate for SMA

...23, 2016) . Roche (SIX:ROG; OTCQX:RHHBY) has two clinical candidates to treat SMA. Its olesoxime (RG6083...
...3, while RG7916 is in Phase II testing to treat types 1, 2 and 3. Olesoxime...
...to treat SMA types 2, 3 and 4 (see BioCentury Extra, Dec. 23, 2014) . Chris Lieu CK-107 CK-2127107 olesoxime RG6083 RG7916 Spinraza SRK-015 Astellas...
BioCentury | Sep 15, 2016
Targets & Mechanisms

KOR-recting MS

...1 (HERVW; ERVW-1) Humanized anti-HERVW mAb GeNeuro S.A. (Euronext:GNRO); Servier Antibody Phase II Olesoxime (RG6083; TRO19622...
BioCentury | Aug 1, 2016
Top Story

Biogen opts in for Ionis' nusinersen on Phase III readout

...for SMA. Next year, Roche (SIX:ROG; OTCQX:RHHBY) hopes to submit regulatory applications for olesoxime ( TRO19622...
BioCentury | Jan 19, 2015
Company News

Trophos, Roche deal

...$142 million) up front and up to ÿ350 million ($414 million) in milestones. Roche gains olesoxime...
...small molecule with cholesterol-like structure that interacts with the mitochondrial permeability transition pore (MPTP) . Olesoxime...
...injury. Roche plans to submit an NDA to FDA and an MAA to EMA for olesoxime...
BioCentury | Jan 17, 2015
Top Story

Roche buys neuromuscular play Trophos

...for up to EUR 350 million ($413.6 million) in milestones. Last year, Trophos' olesoxime ( TRO19622...
...II/III trial to treat spinal muscular atrophy (SMA) (see BioCentury Extra, March 10, 2014) . Olesoxime...
...125-EUR 195 million ($166.4-$259.6 million) under a 2010 deal, but passed on the option after olesoxime...
BioCentury | Mar 17, 2014
Clinical News

Olesoxime: Phase II/III data

...3-25 with type II or non-ambulatory type III SMA showed that once-daily 10 mg/kg oral olesoxime...
...provide details. The product is also in Phase II testing to treat multiple sclerosis (MS). Olesoxime...
...the U.S. and EU to treat SMA. Trophos S.A. , Marseille, France Product: Olesoxime ( TRO19622...
BioCentury | Mar 11, 2014
Clinical News

Trophos reports data for muscular atrophy compound

...Trophos S.A. (Marseille, France) said once-daily oral olesoxime ( TRO19622 ) prevented loss of motor function...
...regulatory applications for the product in the indication, but declined to disclose a time frame. Olesoxime...
Items per page:
1 - 10 of 50